What are the signs, symptoms, types, and detailed management—including high‑dose atropine, oxime therapy, seizure control, and supportive care—of organophosphorus poisoning?

Organophosphorus Poisoning: Comprehensive Clinical Management

Pathophysiology

Organophosphorus compounds irreversibly inhibit acetylcholinesterase, causing life-threatening acetylcholine accumulation at muscarinic, nicotinic, and central nervous system receptors. 1, 2 This enzyme inhibition undergoes "aging"—a process where the chemical bond becomes progressively resistant to reactivation within minutes to hours of exposure. 1, 2

Clinical Presentation: The Cholinergic Crisis

Muscarinic Signs (Parasympathetic Excess)

• Cardiovascular: Bradycardia, hypotension, hemodynamic collapse 1, 2
• Respiratory: Bronchospasm, bronchorrhea (excessive bronchial secretions), respiratory arrest 1, 2
• Secretory: Hypersalivation, lacrimation, urination, diarrhea, diaphoresis (sweating) 1, 2
• Ocular: Miosis (pinpoint pupils) 1, 2
• Gastrointestinal: Vomiting, abdominal cramps, nausea 1

Nicotinic Signs (Neuromuscular Junction Effects)

• Early: Tachycardia, mydriasis (pupil dilation), muscle fasciculations 1, 2
• Late: Depolarizing neuromuscular blockade leading to flaccid paralysis and respiratory muscle failure 1, 2

Central Nervous System Effects

• Anxiety, disorientation, altered mental status 1, 2
• Seizures and generalized convulsions 1, 2
• Central apnea 1, 2
• Coma evolving rapidly to respiratory arrest 1, 2

Types of Organophosphorus Compounds

Pesticides (Most Common in Developing Countries)

• Highly toxic: Methyl parathion (Metacid), Dichlorovos (Nuvan) 3
• Moderately toxic: Dimethoate, Profenofos, Chlorpyrifos 3
• Most poisonings occur via deliberate self-ingestion for suicidal purposes (80% intentional, 20% accidental) 4, 3

Nerve Agents (Chemical Warfare/Terrorism)

• Sarin and other military-grade organophosphates 1
• Exposure occurs within seconds, with rapid progression to respiratory arrest 1

Carbamates

• Structurally similar but spontaneously dissociate from acetylcholinesterase (reversible inhibition) 1
• Do not undergo "aging" and have shorter duration of toxicity 1

Immediate Management (First 5 Minutes)

Personal Protection & Decontamination (Class I, Level B)

Healthcare providers must don full personal protective equipment before any patient contact to prevent secondary contamination. 2 Remove all contaminated clothing immediately and irrigate the patient copiously with soap and water. 1, 2 This prevents further dermal absorption and protects caregivers from exposure. 1, 2

Atropine: The Gold Standard (Class I, Level A)

Administer high-dose atropine immediately for any severe manifestation—this is the single most critical intervention that improves survival. 1, 2

Dosing Protocol

• Initial dose: 2 mg IV for adults, 0.02 mg/kg IV for children 1, 2
• Escalation: Double the dose every 5 minutes until full atropinization is achieved 2
• Cumulative doses: Expect to use 10–20 mg in the first 2–3 hours; total daily doses may reach 50 mg or higher 1, 2
• Highest reported dose: 100 mg IV bolus on admission, 100 mg/hour infusion, with total cumulative dose of 11.6 grams over 12 days 4

Endpoints of Atropinization (Must Achieve All Three)

1. Clear lung fields on auscultation (resolution of bronchorrhea and bronchospasm) 2
2. Heart rate >80 beats/minute 2
3. Systolic blood pressure >80 mmHg 2

Critical Atropine Caveats

• Atropine does NOT reverse nicotinic paralysis or neuromuscular junction blockade—it only antagonizes muscarinic overstimulation 1, 2
• Maintain continuous atropine infusion to sustain endpoints; symptoms will recur if atropine is stopped prematurely 2
• Do not use standard bradycardia doses—organophosphate poisoning requires markedly higher doses 2

Airway Management (Class I, Level B-NR)

Perform early endotracheal intubation in life-threatening organophosphate poisoning—observational data show this improves survival. 2

Neuromuscular Blocker Selection (Class III Contraindication)

• NEVER use succinylcholine or mivacurium—these are metabolized by cholinesterase and will have prolonged, unpredictable effects 2
• Use non-depolarizing agents not dependent on cholinesterase metabolism 2

Adjunctive Therapies (Within 30 Minutes)

Benzodiazepines (Class I, Level C-LD)

Administer benzodiazepines to treat seizures and control agitation—this reduces morbidity. 1, 2

• First-line: Diazepam 0.2 mg/kg IV in fractionated doses 1, 2
• Alternative: Midazolam 0.05–0.1 mg/kg IV 1, 2
• Titrate to effect: seizure cessation and reduced resistance to mechanical ventilation 1, 2

Pralidoxime/Oximes (Class IIa, Level A)

Use pralidoxime as reasonable therapy for organophosphate poisoning, but timing is absolutely critical—it must be given before "aging" occurs. 1, 2

Mechanism & Efficacy

• Oximes compete with the organophosphate-acetylcholinesterase bond, reactivating the enzyme 1, 2
• This reverses nicotinic effects and gradually improves respiratory and skeletal muscle strength 1, 2
• Efficacy is organophosphate-specific and varies among different compounds 2, 5, 6

Dosing

• Initial dose: Pralidoxime chloride (2-PAM) or obidoxime as per local protocols 1
• Repeat dosing: Administer at hourly intervals if progressive worsening or persistent signs of toxicity 1
• Readminister as clinically necessary 1

Critical Oxime Considerations

• Aging timeline: The organophosphate-enzyme bond becomes irreversible within minutes to hours; oximes are ineffective after aging 1, 2
• Carbamate poisoning: Evidence is insufficient to recommend for or against oxime use, but do not withhold oximes when the poison class is unknown 1, 2
• Controversial efficacy: Recent meta-analyses show no significant mortality benefit and possible increased incidence of intermediate syndrome (RR 1.63,95% CI 1.01–2.62) 7
• Despite controversy, the 2023 American Heart Association guideline supports oxime use as Class IIa (reasonable therapy) 1, 2

Gastric Decontamination

• Gastric lavage and activated charcoal are routinely used but their value has not been conclusively proven 3, 8
• Perform only if presentation is within 1–2 hours of ingestion and airway is protected 8

Major Complications & Their Management

Respiratory Failure (Leading Cause of Death)

• Results from combined bronchospasm, bronchorrhea, central apnea, and neuromuscular paralysis 2
• Requires aggressive atropine, early intubation, and mechanical ventilation 2, 4
• Mean duration of mechanical ventilation: 5.73 ± 4.83 days 4

Cardiac Complications

• Severe bradycardia, hypotension, ventricular dysrhythmias, and cardiac arrest 1, 2
• Early atropine administration improves survival in these cardiac events 2

Intermediate Syndrome

• Occurs 24–96 hours after ingestion 7
• Characterized by weakness of neck flexors, respiratory muscles, and proximal limb muscles 7
• May be increased by pralidoxime use (RR 1.63) 7
• Requires continued ventilatory support and atropine 7

Delayed Polyneuropathy

• Rare complication occurring weeks after exposure 3
• Not responsive to acute treatment 3

Novel & Adjunctive Therapies (Investigational)

Emerging Options (Require Further Validation)

• Magnesium sulfate: May decrease acetylcholine release at cholinergic synapses 9, 5
• Calcium channel blockers (nimodipine): Reduce acetylcholine release 9, 5
• Sodium bicarbonate: Plasma alkalinization 9, 5
• β-2 agonists, clonidine, lipid emulsions: Promising alternatives requiring large phase III trials 5, 4
• Hemoperfusion and fresh frozen plasma: Novel modalities deserving further evaluation 9

Critical Pitfalls to Avoid

1. Never delay atropine administration—prompt use improves survival 2
2. Never use inadequate atropine doses—titrate aggressively to defined endpoints, not standard bradycardia protocols 2
3. Never assume atropine reverses paralysis—it only mitigates muscarinic effects; oximes are needed for nicotinic reversal 1, 2
4. Never use succinylcholine or mivacurium for intubation 2
5. Never delay intubation in severe cases—early airway protection improves outcomes 2
6. Never withhold oximes when poison class is uncertain—empirical therapy is recommended 1, 2
7. Never stop atropine prematurely—maintain infusion until secretions completely resolve 4, 3
8. Never underestimate required atropine supply—ensure hospitals stock sufficient quantities (grams, not milligrams) 4

Monitoring & Disposition

Laboratory Diagnosis

• Plasma cholinesterase levels: Confirm diagnosis but do not delay treatment 9, 3
• Red blood cell acetylcholinesterase is more specific but less readily available 1

Intensive Care Requirements

• Mean ICU stay: 6.52 ± 4.80 days 4
• Continuous monitoring of respiratory status, cardiac rhythm, and neurological function 4
• 92% discharge rate in good clinical condition with aggressive management 4

Prognosis Factors

• Type of organophosphate compound 9
• Time from exposure to treatment 9
• Severity of initial presentation (Glasgow Coma Scale <8 indicates poor prognosis) 4
• Adequacy of atropine dosing 4